My understanding was Coviu and Phenix Health integrations would mean ResAppDx is embedded natively on each Telehealth platform so every physician has immediate access to this tool.
It was revealed yesterday this is not the case, ResAppDx is a merely a third party "add on" which has to be requested by the physician to be installed. The benefits then need to be persuaded to the patient who has to pay out of pocket.
Without any large scale cost benefit analysis from reputable medical bodies, there is no compelling reason for physicians to experiment with ResAppDx at this stage. Hence the low uptake, it has nothing to do with "low seasonal flu rates".
These Telehealth companies additionally are in a once in a business cycle opportunity to drive customer acquisitions. They are not interested in taking on ResApps marketing challenge.
Most of the call was about SleepCheck which says it all, you would be forgiven for thinking this company is called SleepCheck Health.
Another case of incredible product and viable business model but abysmal execution.
RAP Price at posting:
9.0¢ Sentiment: None Disclosure: Not Held
